Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1993 Apr; 67(4): 856–860.
PMCID: PMC1968338

Advanced breast cancer: use of resources and cost implications.


Little information is currently available on the use of hospital resources and the resulting costs of treating any advanced cancer. Such data may be useful for planning purposes and for calculating the cost effectiveness of measures designed to reduce the incidence of advanced disease (such as the National Breast Screening Programme). A retrospective analysis of the medical records of 50 patients with advanced breast cancer who attended the Guy's Hospital Oncology Unit and who died between October 1988 and December 1990 has therefore been undertaken. For each patient, the duration of in-patient stays and principal indications for admissions were recorded, together with the number of out-patient attendances. Details of endocrine treatment, chemotherapy and radiotherapy were abstracted as were all radiological and laboratory investigations. Costs for each of these activities were calculated. The median duration of advanced disease was 17 months (mean 27 months; range 7 days-12 years). The mean cost of treatment per patients was calculated to be 7,620 pounds (range 317 pounds-27,860 pounds). Mean duration of in-patient stay was 32 days (0-133) and this accounted for 56% of total costs. The large majority (> 80%) of the time spent as an in-patient was for the care of serious illness rather than for specific antitumour treatment. Cytotoxic drugs accounted for 9% of the total cost, compared with 8% for radiotherapy and 13% for laboratory and radiological investigations.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Atherton L. The cost of radiotherapy treatments on a linear accelerator. Br J Radiol. 1984 Jan;57(673):106–107. [PubMed]
  • Baker MS, Kessler LG, Urban N, Smucker RC. Estimating the treatment costs of breast and lung cancer. Med Care. 1991 Jan;29(1):40–49. [PubMed]
  • Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, Perez CA, Hendrickson FR. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980 Jan;6(1):1–9. [PubMed]
  • de Koning HJ, van Ineveld BM, de Haes JC, van Oortmarssen GJ, Klijn JG, van der Maas PJ. Advanced breast cancer and its prevention by screening. Br J Cancer. 1992 Jun;65(6):950–955. [PMC free article] [PubMed]
  • Ellis BW. Management importance of common treatments: contribution of top 20 procedures to surgical workload and cost. BMJ. 1991 Apr 13;302(6781):882–884. [PMC free article] [PubMed]
  • Friedlander ML, Tattersall MH. Counting the costs of cancer therapy. Eur J Cancer Clin Oncol. 1982 Dec;18(12):1237–1241. [PubMed]
  • Gelber RD, Larson M, Borgelt BB, Kramer S. Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis. Cancer. 1981 Oct 15;48(8):1749–1753. [PubMed]
  • Goddard M, Maher EJ, Hutton J, Shah D. Palliative radiotherapy--counting the costs of changing practice. Health Policy. 1991 Apr;17(3):243–256. [PubMed]
  • Greene D. The cost of radiotherapy treatments on a linear accelerator. Br J Radiol. 1983 Mar;56(663):189–191. [PubMed]
  • Hurley SF, Huggins RM, Snyder RD, Bishop JF. The cost of breast cancer recurrences. Br J Cancer. 1992 Mar;65(3):449–455. [PMC free article] [PubMed]
  • Lobo PJ, Powles RL, Hanrahan A, Reynold DK. Acute myeloblastic leukaemia--a model for assessing value for money for new treatment programmes. BMJ. 1991 Feb 9;302(6772):323–326. [PMC free article] [PubMed]
  • Mattsson W, Gynning I, Carlsson B, Mauritzon SE. Cancer chemotherapy in advanced malignant disease. A cost benefit analysis. Acta Radiol Oncol Radiat Phys Biol. 1979;18(6):509–520. [PubMed]
  • Rubens RD. Auditing palliative cancer chemotherapy. Eur J Cancer. 1990;26(10):1023–1025. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...